Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial

NCT ID: NCT04622397

Last Updated: 2020-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-10

Study Completion Date

2021-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hypothesized that local administration of tranexamic acid will minimize blood loss and blood product administration in pediatric patient undergoing scoliosis surgery

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spine surgery in paediatrics is frequently associated with substantial blood loss.

Blood product adminestration in children has many complications that are not fully known.

There are many modalities currently available to reduce blood loss in pediatric patients.

Tranexamic acid is tissue plasminogen activator inhibitor that reduce perioperative blood loss.

To date, no studies have investigated effect of local administration of tranexamic acid in pediatric population undergoing scoliosis surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Loss, Surgical Scoliosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized comparative study
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Caregivers
surgeon will be blinded to type of injection

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group T (tranexamic acid),n=15

Group T: tranexamic acid 10 mg/kg will be injected locally

Group Type ACTIVE_COMPARATOR

Tranexamic acid injection

Intervention Type DRUG

Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision

Group S (saline) (n=15)

Group S saline will be injected

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid injection

Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision

Intervention Type DRUG

Saline

Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 2-12 years
* Of both sexes
* American society of anesthesiologist (ASA) physical status classification class I
* Undergoing general anesthesia for scoliosis surgery

Exclusion Criteria

* Parents' refusal of regional block
* Known allergy to tranexamic acid
* Bleeding disorders (INR \>1.4,Platelet count\< 75000)
Minimum Eligible Age

2 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mina Adolf Helmy

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mina Adolf Helmy, MD

Role: CONTACT

Phone: 2001275716942

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Bible JE, Mirza M, Knaub MA. Blood-loss Management in Spine Surgery. J Am Acad Orthop Surg. 2018 Jan 15;26(2):35-44. doi: 10.5435/JAAOS-D-16-00184.

Reference Type BACKGROUND
PMID: 29303921 (View on PubMed)

Goobie SM. A blood transfusion can save a child's life or threaten it. Paediatr Anaesth. 2015 Dec;25(12):1182-3. doi: 10.1111/pan.12816. No abstract available.

Reference Type BACKGROUND
PMID: 26507915 (View on PubMed)

Mikhail C, Pennington Z, Arnold PM, Brodke DS, Chapman JR, Chutkan N, Daubs MD, DeVine JG, Fehlings MG, Gelb DE, Ghobrial GM, Harrop JS, Hoelscher C, Jiang F, Knightly JJ, Kwon BK, Mroz TE, Nassr A, Riew KD, Sekhon LH, Smith JS, Traynelis VC, Wang JC, Weber MH, Wilson JR, Witiw CD, Sciubba DM, Cho SK. Minimizing Blood Loss in Spine Surgery. Global Spine J. 2020 Jan;10(1 Suppl):71S-83S. doi: 10.1177/2192568219868475. Epub 2020 Jan 6.

Reference Type BACKGROUND
PMID: 31934525 (View on PubMed)

Slaughter TF, Greenberg CS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997 Sep;56(1):32-6. doi: 10.1002/(sici)1096-8652(199709)56:13.0.co;2-3.

Reference Type BACKGROUND
PMID: 9298865 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

tranexamic acid in scoliosis

Identifier Type: -

Identifier Source: org_study_id